Advertisement

Topics

Prolx Pharmaceuticals LP Company Profile

18:37 EST 18th November 2017 | BioPortfolio

PROLX Pharmaceuticals is a privately held biopharmaceutical company dedicated to the discovery of novel target-based therapeutics for the treatment of cancer. PROLX was established to rapidly move novel, proprietary, small molecule pharmaceuticals through pre-clinical development and into clinical trials. Seminal research being conducted by PROLX in collaboration with several leading universities provides the Company with world renowned combinatorial chemistry capabilities, cellular and genetic screening technologies, and is yielding a robust pipeline of new cancer therapies.





PROLX’s approach to cancer drug discovery is to develop drugs that block the activity of redox regulating and survival signaling cellular protein targets that provide a growth advantage to cancer cells. PROLX has the exclusive worldwide rights to a redox regulating cancer-causing gene product and to compounds that inhibit its cancer-causing biological activity. In addition to its lead clinical candidate, PX-12, which is entering a clinical trial in 2001, this target-directed approach to cancer drug discovery is expected to yield novel, potent cancer-specific chemotherapeutics.

Location

1401 Forbes Avenue Suite 231
Pittsburgh
PA
15219
United States of America

Contact

Phone: (412) 201-2477
Fax: (412) 281-2462
Email: info@prolx.com


News Articles [446 Associated News Articles listed on BioPortfolio]

Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals

Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery technology.

Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals

Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.

Contrasting Pacira Pharmaceuticals

Pacira Pharmaceuticals and Lannett Co are both small-cap pharmaceuticals - nec companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings...

Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean

TORONTO, ON -- (Marketwired) -- 09/12/17 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has receiv...

Imprimis launches Surface Pharmaceuticals subsidiary

Imprimis Pharmaceuticals, an ophthalmology-focused pharmaceutical company, has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary, Surface Pharmaceuticals. Surf...

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES, CA -- (Marketwired) -- 08/07/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modu...

FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) for Travelers' Diarrhea

Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial Efforts Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the U.S. Food and Drug Administration (FDA) has granted b...

Deals this week: Valeant Pharmaceuticals International, Novan, Recursion Pharmaceuticals

Valeant Pharmaceuticals International plans to raise C$1bn ($801.37m) through the private placement of senior secured notes.

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [120 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Effects of exposure to pharmaceuticals (diclofenac and carbamazepine) spiked sediments in the midge, Chironomus riparius (Diptera, Chironomidae).

Human and veterinary pharmaceuticals and degradation products are continuously introduced into the environment. To date, there is a lack of information about the effects of pharmaceuticals in spiked t...

Clinical Trials [206 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1286 Associated Companies listed on BioPortfolio]

ProlX Pharmaceuticals, Corp.

ProlX Pharmaceuticals (ProlX) is a biopharmaceutical company dedicated to the discovery of novel therapeutics for the treatment of cancer. The Company is building a diversified pipeline utilizing a ta...

Prolx Pharmaceuticals LP

PROLX Pharmaceuticals is a privately held biopharmaceutical company dedicated to the discovery of novel target-based therapeutics for the treatment of cancer. PROLX was established to rapidly move no...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Prolx Pharmaceuticals LP" on BioPortfolio

We have published hundreds of Prolx Pharmaceuticals LP news stories on BioPortfolio along with dozens of Prolx Pharmaceuticals LP Clinical Trials and PubMed Articles about Prolx Pharmaceuticals LP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prolx Pharmaceuticals LP Companies in our database. You can also find out about relevant Prolx Pharmaceuticals LP Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record